Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vistagen Therapeutics Inc (NQ: VTGN )

2.690 UNCHANGED
Streaming Delayed Price Updated: 9:54 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
Via Investor Brand Network
Preview: VistaGen Therapeutics's Earnings
Via Benzinga
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. 
Via Benzinga
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
Via Investor Brand Network
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
From Vistagen
Via Business Wire
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
Via Investor Brand Network
Exposures Product Safety
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
Via Investor Brand Network
Exposures Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 
Via News Direct
Exposures Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
By Rachael Green, Benzinga 
Via TheNewswire.com
Exposures Product Safety
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial
Via Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
From Vistagen
Via Business Wire
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
Via Investor Brand Network
Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition
Via Benzinga
Vistagen to Acquire Pherin Pharmaceuticals
From Vistagen
Via Business Wire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.